Cambridge Investment Research Advisors Inc. trimmed its holdings in Edwards Lifesciences Corp (NYSE:EW) by 1.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,038 shares of the medical research company’s stock after selling 292 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Edwards Lifesciences were worth $3,780,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Hoylecohen LLC increased its stake in Edwards Lifesciences by 6.2% during the 1st quarter. Hoylecohen LLC now owns 1,648 shares of the medical research company’s stock valued at $311,000 after buying an additional 96 shares during the period. First Pacific Advisors LP acquired a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $118,000. Frontier Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $281,000. First Allied Advisory Services Inc. increased its stake in shares of Edwards Lifesciences by 15.7% during the first quarter. First Allied Advisory Services Inc. now owns 4,004 shares of the medical research company’s stock valued at $755,000 after acquiring an additional 544 shares during the period. Finally, Cetera Advisor Networks LLC raised its holdings in Edwards Lifesciences by 39.2% during the first quarter. Cetera Advisor Networks LLC now owns 2,761 shares of the medical research company’s stock worth $521,000 after purchasing an additional 778 shares in the last quarter. Hedge funds and other institutional investors own 81.22% of the company’s stock.
Shares of EW stock opened at $218.81 on Friday. The company has a market capitalization of $45.13 billion, a price-to-earnings ratio of 41.84, a P/E/G ratio of 2.75 and a beta of 0.85. Edwards Lifesciences Corp has a 1-year low of $154.52 and a 1-year high of $247.64. The company has a current ratio of 3.36, a quick ratio of 2.47 and a debt-to-equity ratio of 0.17. The stock’s fifty day simple moving average is $212.94 and its 200-day simple moving average is $222.43.
A number of equities analysts have issued reports on the company. Citigroup lifted their price target on Edwards Lifesciences from $240.00 to $255.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Barclays reaffirmed an “underweight” rating and set a $155.00 target price (down from $165.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $231.00 price target on the stock in a research report on Monday, February 3rd. BTIG Research restated a “hold” rating on shares of Edwards Lifesciences in a research report on Thursday, April 23rd. Finally, UBS Group boosted their target price on shares of Edwards Lifesciences from $255.00 to $260.00 and gave the stock a “neutral” rating in a report on Friday, January 31st. One analyst has rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $247.52.
In related news, VP Catherine M. Szyman sold 750 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $216.93, for a total value of $162,697.50. Following the completion of the sale, the vice president now owns 18,318 shares of the company’s stock, valued at approximately $3,973,723.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Catherine M. Szyman sold 1,116 shares of the stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $162.95, for a total transaction of $181,852.20. Following the transaction, the vice president now directly owns 15,773 shares in the company, valued at $2,570,210.35. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,878 shares of company stock valued at $20,047,408. 1.48% of the stock is owned by corporate insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Read More: Compound Interest
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.